IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
12 mai 2022 08h00 HE
|
IN8bio, Inc
Phase 1 clinical trial of INB-100 in leukemia patients and INB-200 in newly diagnosed glioblastoma multiforme (GBM) patients continue to generate encouraging data.INB-100 patient update at European...
IN8bio Unveils Induced Pluripotent Stem Cell (iPSC) Platform at ASGCT 25th Annual Meeting
05 mai 2022 08h00 HE
|
IN8bio, Inc
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of gamma-delta T cell therapies, today...
IN8bio to Present at May Investor and Scientific Conferences
04 mai 2022 08h00 HE
|
IN8bio, Inc
NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies...
IN8bio Continues to Build on its Clinical and Regulatory Team with Two Key Appointments
13 avr. 2022 08h30 HE
|
IN8bio, Inc
Urvashi Patel, Ph.D., as Vice President, Regulatory AffairsStacey Bilinski, as Vice President, Clinical Operations NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a...
IN8bio to Present at April Investor and Scientific Conferences
05 avr. 2022 16h15 HE
|
IN8bio, Inc
NEW YORK, April 05, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell...
IN8bio Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
28 mars 2022 08h00 HE
|
IN8bio, Inc
All three patients with high-risk or relapsed acute-myeloid leukemia (AML) dosed to-date with INB-100 demonstrated durable remissions at 23.3, 21.0, and 9.3 months post-BMT, respectively. Immune...
IN8bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
17 mars 2022 16h15 HE
|
IN8bio, Inc
All patients treated with INB-200, in clinical development for the treatment of glioblastoma multiforme (GBM), have shown a well-tolerated safety profile and longer than anticipated progression free...
IN8bio to present at March Investor and Scientific Conferences
04 mars 2022 07h00 HE
|
IN8bio, Inc
NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage gamma-delta T cell therapies biopharmaceutical company, today announced March conference presentations: ...
IN8bio to present at Bio CEO & Investor Conference and Next Generation CAR-TCR Summit
10 févr. 2022 17h36 HE
|
IN8bio, Inc
NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage gamma-delta T cell therapies biopharmaceutical company today announced that Company executives will be...
IN8bio to Present at Upcoming January Investor Conferences
10 janv. 2022 07h00 HE
|
IN8bio, Inc
NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell...